Cost effectiveness of intensive treatment of hypertension

American Journal of Managed Care

Volumn 4, Issue 12 SUPPL., 1998, Pages

  Shepard, Donald S ^a   Hodgkin, Dominic ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISABILITY; DRUG COST; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ANTIHYPERTENSIVE AGENTS; ASPIRIN; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 0032411995     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (6)

1. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.
2. Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics. Cincinnati, OH: Harvey Whitney Books Co.;1996.
3. Shepard D, Thompson M. First principles of cost-effectiveness analysis in health. Public Health Reports 1979;94:535-542.
4. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) study: 24-month data on blood pressure and tolerability. Blood Pressure 1997;6: 313-317.
5. Weinstein MC, Stason WB, Blumenthal D, McNeil BJ, Nichols AL, Shepard DS. Hypertension: A policy perspective. Cambridge, MA: Harvard University Press; 1996.
6. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992;327:7-13.